Evaluation of the Excretion of Fosfomycin Into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women
Evaluation of the Excretion of Fosfomycin into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Evaluation of the Excretion of Fosfomycin into Breast Milk Following a Single Intravenous Dose of ZTI-01 (6 g) in Healthy Lactating Women
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 4단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Meitheal Pharmaceuticals, Inc. Meitheal Pharmaceuticals, Inc.
- 전화번호: (224) 443-4617
- 이메일: info@meithealpharma.com
연구 장소
-
-
-
Bloemfontein, 남아프리카, 9301
- 모병
- FARMOVS (Pty) Ltd
-
연락하다:
- Meitheal Meitheal
- 전화번호: (224) 443-4617
- 이메일: info@meithealpharma.com
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participant must be 18 to 45 years of age inclusive, at the time of signing the informed consent.
- Participant is a healthy lactating female, who is actively breastfeeding (including baby to breast, bottle feeding mother's expressed breast milk) and is at least 12 weeks postpartum of a healthy term (≥ 37 weeks gestational age) newborn infant (no medical complications) and not more than 1 years postpartum. Lactation must be well established prior to the day of admission to inpatient unit.
- Participant is overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and 12-lead ECG at screening.
- Participant is willing to temporarily discontinue breastfeeding their infant and discard all their breast milk for 5 consecutive days, including (day of admission to inpatient unit (Day -1), day of dosing while in the inpatient unit (Day 1), and 3 consecutive days after dose (including the day of discharge from the inpatient unit and 2 days at home; Days 2 to 4); and willing to store sufficient amount of breastmilk (e.g., breast milk pumped and stored in freezer before the day of admission), and/or infant formula to feed infant during these 5 consecutive days.
- Participant must not be in the process of weaning before admission to inpatient unit and have maintained an adequate breast milk supply (according to Investigator discretion) with regularly pumping or routine breastfeeding (e.g., pumping or feeding 3-4 times a day) at admission.
- Participant has a body mass index (BMI) within the range 18 to 35 kg/m2 (inclusive)
- Participant is either sexually inactive (abstinent) or, if sexually active, must agree to use/practice one of the acceptable birth control methods listed in Section 10.3 beginning before or during the screening period prior to the first dose, throughout the inpatient stay, and for 3 days following the dose.
- Signed informed consent as described in Section 10.1.1.3 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Willingness to follow protocol defined restrictions and Investigator/staff instructions and protocol procedures.
- Agrees to use only the emollient or nipple cream recommended by the investigator for use during the sampling period, if needed.
Exclusion Criteria:
- Participant is pregnant or plans to become pregnant during the course of the study.
- Sensitivity to any of the study interventions, or components thereof, or other allergy that, in the opinion of the Investigator, contraindicates participation in the study.
- History or presence of cardiovascular, respiratory, psychiatric, metabolic, hepatic, renal, gastrointestinal, endocrinological, hematological, oncological, or neurological disorders determined to be clinically significant by the Investigator.
- History or presence of any condition that in the opinion of the Investigator would constitute a risk when taking the study intervention or interfere with the interpretation of data.
- History or presence of drug or alcohol abuse or current alcohol use > 21 units of alcohol per week (1 unit is equal to approximately 330 mL of beer, 1 small glass [200 mL] of wine, or 1 measure [25 mL] of spirits).
- History or regular use of tobacco- or nicotine-containing products within 6 months prior to screening with the exception of casual smokers (i.e., < 5 cigarettes per week).
- Has history of mastitis within 30 days, breast cancer and/or has had a mastectomy or lumpectomy with the exception of a benign fibroma or lipoma removal at the investigator's discretion; and/or a clinically significant abnormality observed in either breast during a clinical breast exam at Screening or Admission (Day -1).
- Past or intended use of prescription medication within 14 days or over-the-counter medication including herbal medications within 7 days prior to dosing (apart from vitamin/mineral supplements or occasional paracetamol).
- Current enrollment or past participation in another investigational study in which an investigational intervention (e.g., drug, vaccine, invasive device) was administered within 90 days or 5 half-lives (whichever is longer) before planned first dose of study intervention in this clinical study.
- Positive drug/alcohol screen at screening or Day -1. At screening visit, in case of a positive result the urine screen for drugs of abuse may be repeated once at the discretion of the Investigator.
- Evidence of human immunodeficiency virus (HIV) infection and/or positive human HIV antibodies at screening; positive test results for hepatitis B surface antigen (HBsAg), immunoglobulin M (IgM) antibody to hepatitis B core antigen (anti-HBc), or hepatitis C virus (HCV Ab) antibodies at screening.
- Positive pregnancy test at screening or Day -1.
- Clinically significant vital signs, ECG findings, or laboratory abnormalities, including CrCl ≤ 50 mL/min.
- Has history of breast implants, breast augmentation, or breast reduction surgery.
- Unwilling to abstain from alcohol for 48 hours prior to dosing through the duration of confinement.
- Employees or close relatives of the contract service providers, the sponsor, 3rd party vendors or affiliates of the above mentioned parties.
- Vulnerable participants (e.g., persons in detention).
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 다른
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
다른: ZTI-01
Participants will receive single intravenous dose of ZTI-01 (6 g) |
Participants will receive a single intravenous dose of ZTI-01 (6 g) |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Area under the concentration-time curve for drug concentrations in breast milk from time 0 to 24 hours (AUC0-24h,milk)
기간: 0-24 hours post dose
|
To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose |
0-24 hours post dose
|
|
Maximum observed drug concentration in breast milk (Cmax,milk)
기간: 0-24 hours post dose
|
To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose |
0-24 hours post dose
|
|
Time to reach the maximum observed drug concentration in breast milk (Tmax,milk)
기간: 0-24 hours post dose
|
To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose |
0-24 hours post dose
|
|
Average drug concentration in breast milk (Cave,milk), calculated as AUC₀-24h, milk divided by Tau (τ)
기간: 0-24 hours post dose
|
To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose |
0-24 hours post dose
|
|
Total amount of drug in breast milk over a period of 24 hours (Ammilk, mg/day) following a single dose
기간: 0-24 hours post dose
|
To evaluate the PK of ZTI-01 in breast milk in healthy lactating women following a single intravenous dose |
0-24 hours post dose
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Estimated daily infant dosage (EDID, mg/kg/day)
기간: 0-24 hours post dose
|
To estimate daily infant dose of ZTI-01 via breast milk |
0-24 hours post dose
|
|
Relative infant dose (RID, %)
기간: 0-24 hours post dose
|
To estimate daily infant dose of ZTI-01 via breast milk |
0-24 hours post dose
|
|
Adverse event (AE) assessments
기간: Baseline (Day 1) to End of Study (Day 4)
|
To assess the safety and tolerability of ZTI-01 in healthy lactating women |
Baseline (Day 1) to End of Study (Day 4)
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- ZTI-01-401
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .